These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 709096)

  • 21. Direct measurement of chlormethiazole extraction by liver, lung and kidney in man.
    Mather LE; Runciman WB; Ilsley AH; Thomson KR; Goldin AR
    Br J Clin Pharmacol; 1981 Sep; 12(3):319-25. PubMed ID: 7295462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics of molsidomine and its active metabolite, linsidomine, in patients with liver cirrhosis.
    Spreux-Varoquaux O; Doll J; Dutot C; Grandjean N; Cordonnier P; Pays M; Andrieu J; Advenier C
    Br J Clin Pharmacol; 1991 Sep; 32(3):399-401. PubMed ID: 1777378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics of tolfenamic acid in patients with cirrhosis of the liver.
    Stenderup J; Eriksen J; Pedersen SB; Christiansen LV
    Eur J Clin Pharmacol; 1985; 28(5):573-9. PubMed ID: 3876221
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prolonged infusion of chlormethiazole in intensive care.
    Scott DB; Beamish D; Hudson IN; Jostell KG
    Br J Anaesth; 1980 May; 52(5):541-5. PubMed ID: 7387809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An integrated study of pharmacokinetics and pharmacodynamics of chlormethiazole in healthy young volunteers.
    Seow LT; Mather LE; Roberts JG
    Eur J Clin Pharmacol; 1981 Mar; 19(4):263-9. PubMed ID: 7286029
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Furosemide disposition in cirrhotic patients.
    Sawhney VK; Gregory PB; Swezey SE; Blaschke TF
    Gastroenterology; 1981 Dec; 81(6):1012-6. PubMed ID: 7286579
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preferential reduction of first-pass elimination by ethanol. Model experiments with clomethiazole in the rabbit.
    Zysset T; Bircher J
    J Pharmacol Exp Ther; 1981 Apr; 217(1):198-203. PubMed ID: 7205653
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ranitidine disposition in severe hepatic cirrhosis.
    Gonzalez-Martin G; Paulos C; Veloso B; Chesta J; Novoa X; Arancibia A
    Int J Clin Pharmacol Ther Toxicol; 1987 Mar; 25(3):139-42. PubMed ID: 3557740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of alcholic delirium].
    Baer R
    Dtsch Med Wochenschr; 1975 Apr; 100(15):829-30. PubMed ID: 1122834
    [No Abstract]   [Full Text] [Related]  

  • 30. Treatment of liver disease with malotilate. A pharmacokinetic and pharmacodynamic phase II study in cirrhosis.
    Bührer M; Le Cotonnec JY; Wermeille M; Bircher J
    Eur J Clin Pharmacol; 1986; 30(4):407-16. PubMed ID: 3743616
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
    Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
    Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral and intravenous pharmacokinetics of ranitidine in patients with liver cirrhosis.
    Okolicsanyi L; Venuti M; Strazzabosco M; Orlando R; Nassuato G; Iemmolo RM; Lirussi F; Muraca M; Pastorino AM; Castelli G
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):329-32. PubMed ID: 6086536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Temazepam clearance unaltered in cirrhosis.
    Ochs HR; Greenblatt DJ; Verburg-Ochs B; Matlis R
    Am J Gastroenterol; 1986 Jan; 81(1):80-4. PubMed ID: 2867675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of cirrhosis and ageing on the elimination and bioavailability of ranitidine.
    Young CJ; Daneshmend TK; Roberts CJ
    Gut; 1982 Oct; 23(10):819-23. PubMed ID: 6126422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Furosemide absorption in patients with cirrhosis.
    Fredrick MJ; Pound DC; Hall SD; Brater DC
    Clin Pharmacol Ther; 1991 Mar; 49(3):241-7. PubMed ID: 2007318
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of glafenine and glafenic acid in patients with cirrhosis, compared to healthy volunteers.
    Vermerie N; Kusielewicz D; Tod M; Nicolas P; Perret G; Fauvelle F; Petitjean O
    Fundam Clin Pharmacol; 1992; 6(4-5):197-203. PubMed ID: 1358775
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Kinetics of chlormethiazole in patients with alcohol withdrawal manifestations.
    Jostell KG; Agurell S; Hollister LE; Wermuth B
    Clin Pharmacol Ther; 1978 Feb; 23(2):181-7. PubMed ID: 620478
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cimetidine disposition in patients with Laennec's cirrhosis during multiple dosing therapy.
    Cello JP; Oie S
    Eur J Clin Pharmacol; 1983; 25(2):223-9. PubMed ID: 6628505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Unusual courses of alcoholic delirium under treatment with Distraneurin].
    Böcker F
    Med Monatsschr; 1973 Dec; 27(12):558-9. PubMed ID: 4786604
    [No Abstract]   [Full Text] [Related]  

  • 40. Binding and disposition of sulfisoxazole in alcoholic cirrhosis.
    Cello JP; Oie S
    J Pharmacokinet Biopharm; 1985 Feb; 13(1):1-12. PubMed ID: 4020620
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.